Short-term immunotherapy: A prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis

Hans Peter Zenner, Claus Baumgarten, Gerd Rasp, Thomas Fuchs, Gert Kunkel, Bettina Hauswald, Johannes Ring, Isaak Effendy, Wolfram Behrendt, Peter J. Frosch, Bernhard Przybilla, Franz X. Brunner, Hans F. Merk, Alexander Kapp, Jörg Schnitker, Hendrik Wolf

Research output: Contribution to journalArticlepeer-review

62 Scopus citations

Abstract

Background: Short-term immunotherapy (STI) can be beneficial for patients who are noncompliant with long-term specific immunotherapy. Objective: The efficacy and tolerance of STI with seven preseasonal injections of molecular standardized allergens from grass and rye pollen has been investigated in a double-blind, placebo-controlled multicenter study with 87 patients at 12 German University hospitals. Methods: Symptoms of the eyes, nose, and bronchi and use of symptomatic drugs were documented daily in diaries by patients with allergic rhinitis to grass and/or rye pollen and without bronchial asthma. Patients were monitored by skin prick test titration and measurement of levels of specific IgE and IgG4. Results: The median nasal score for the 10 weeks with the strongest symptoms during the grass pollen season was significantly lower (p = 0.014) with 35.0 for STI (n = 41) versus 69.0 for placebo (n = 40); the overall symptom score was 54.0 for STI versus 97.5 for placebo (p = 0.020). Only STI-treated patients exposed to less than 40 pollen grains per cubic meter per week showed a significantly lower nasal symptom score of 39.0 versus 75.0 for placebo (p = 0.006); these patients also had fewer nasal symptoms and less use of topical nasal drugs (p < 0.001). The threshold dose in skin prick tests was significantly higher, being 9.06 histamine equivalent for skin prick test (HEP) for STI-treated patients who received the maximum dose (n = 22) versus 4.33 HEP for placebo (p = 0.005). Specific IgE levels were significantly higher, being 55.9 SU/ml for STI versus 39.2 SU/ml for placebo after seven injections (p = 0.006) and level of specific IgG4 was 5.36% for STI versus 1.28% for placebo (p < 0.001). No severe systemic reactions were observed. Conclusion: STI with seven preseasonal injections with molecular standardized allergens is effective and well tolerated.

Original languageEnglish
Pages (from-to)23-29
Number of pages7
JournalJournal of Allergy and Clinical Immunology
Volume100
Issue number1
DOIs
StatePublished - 1997

Keywords

  • Allergic rhinitis
  • Grass pollen
  • Rye pollen
  • Short-term immunotherapy
  • Skin prick test
  • Specific IgE
  • Specific IgG4
  • Specific immunotherapy

Fingerprint

Dive into the research topics of 'Short-term immunotherapy: A prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis'. Together they form a unique fingerprint.

Cite this